Literature DB >> 21489827

Efficacy of intravenous lacosamide in refractory nonconvulsive status epilepticus and simple partial status epilepticus.

Kristin Rantsch1, Uwe Walter, Matthias Wittstock, Reiner Benecke, Johannes Rösche.   

Abstract

Nonconvulsive status epilepticus (NCSE) and epilepsia partialis continua (EPC) are common epileptic conditions for which straightforward recommendations based on controlled randomized trials for treatment in therapy refractory courses are lacking. In a large retrospective study on drug efficacy in status epilepticus (SE) we identified the patients treated in our department by searching for the term "status epilepticus" in the electronic archive of medical reports of our clinic. Here we present the subset of data concerning the patients treated with lacosamide (LCM). Ten episodes of SE in nine patients could be analyzed. To control for age dependency of results at discharge we calculated a Spearman correlation coefficient with age as independent variable and return to baseline Modified Rankin Score (mRS) at discharge=1, worsening of condition at discharge (i.e. new neurological deficit or worsening of mRS)=2 and death in hospital=3 as dependent variables. LCM was given in dosages of 50-100mg. It was not earlier administered than as fourth drug. Nevertheless it seemed to be effective for termination of status epilepticus in 20% of the episodes. But the outcome at discharge seemed considerably to depend on age of patients (r=0.94, explaining 89% of variance).
Copyright © 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21489827     DOI: 10.1016/j.seizure.2011.03.010

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  7 in total

Review 1.  Novel medications for epilepsy.

Authors:  Cinzia Fattore; Emilio Perucca
Journal:  Drugs       Date:  2011-11-12       Impact factor: 9.546

2.  Safety and efficacy of lacosamide in the intensive care unit.

Authors:  Sunil Cherry; Lilith Judd; Juan Carlos Muniz; Hoda Elzawahry; Suzette LaRoche
Journal:  Neurocrit Care       Date:  2012-04       Impact factor: 3.210

3.  The Safety and Effectiveness of Intravenous Lacosamide for Refractory Status Epilepticus in the Critically Ill.

Authors:  C R Newey; N M Le; C Ahrens; P Sahota; S Hantus
Journal:  Neurocrit Care       Date:  2017-04       Impact factor: 3.210

Review 4.  The efficacy of lacosamide as monotherapy and adjunctive therapy in focal epilepsy and its use in status epilepticus: clinical trial evidence and experience.

Authors:  Sebastian Bauer; Laurent M Willems; Esther Paule; Christine Petschow; Johann Philipp Zöllner; Felix Rosenow; Adam Strzelczyk
Journal:  Ther Adv Neurol Disord       Date:  2016-11-29       Impact factor: 6.570

5.  Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study.

Authors:  Raoul Sutter; Stephan Marsch; Stephan Rüegg
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

6.  Intravenous lacosamide in refractory seizure clusters and status epilepticus: comparison of 200 and 400 mg loading doses.

Authors:  Benjamin Legros; Chantal Depondt; Marcel Levy-Nogueira; Noémie Ligot; Nicolas Mavroudakis; Gilles Naeije; Nicolas Gaspard
Journal:  Neurocrit Care       Date:  2014-06       Impact factor: 3.210

7.  Treatment of refractory simple partial status epilepticus by the addition of oral lacosamide in neurosurgical patients. Report of 3 cases.

Authors:  Georgios F Hadjigeorgiou; Adamantios Petsanas; Christos Anagnostopoulos; Christos Chamilos; Georgios Vranos; Philokypros Spyridakis
Journal:  Epilepsy Behav Case Rep       Date:  2013-05-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.